<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02826213</url>
  </required_header>
  <id_info>
    <org_study_id>PHRI14-JCV-RENOMAP</org_study_id>
    <nct_id>NCT02826213</nct_id>
  </id_info>
  <brief_title>Comparison of Two Techniques of Renal Pre-transplant Infusion on the Evolution of Renal Function in the Recipient</brief_title>
  <acronym>RENOMAP</acronym>
  <official_title>Comparison of Two Techniques of Renal Pre-transplant Infusion on the Evolution of Renal Function in the Recipient: Multicentre Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of two techniques of renal pre-transplant infusion on the evolution of renal&#xD;
      function in the recipient: multicentre randomized trial&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Both machines differ in their operation: the LifePort® machine manufactured by the &quot;Organ&#xD;
      Recovery System (ORS),&quot; says renal perfusion by maintaining a continuous perfusion pressure&#xD;
      that is adjustable, while the Waves machine company &quot;Medical Waters&quot; assures infusion&#xD;
      maintaining a controlled pulsatile flow.&#xD;
&#xD;
      Both machines are now available but the investigators currently have no study of whether an&#xD;
      infusion type is superior to the other in terms of results on renal function recipients.&#xD;
&#xD;
      Study the impact of both types of infusion on renal function recipients evaluated in the&#xD;
      early days of transplantation, at three months and one year after the transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Glomerular Filtration Rate</measure>
    <time_frame>3 months</time_frame>
    <description>Rate of patients with a Glomerular Filtration Rate (GFR) calculated by the MDRD ≥ 45 ml / min / 1,73m² (considered normal in a renal graft) at 3 months post-transplantation (MDRD: Modification of Diet in Renal the Disease)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Creatinine &lt;250 mg / dL</measure>
    <time_frame>1 week</time_frame>
    <description>Time for obtaining a serum creatinine &lt;250 mg / dL and need for dialysis in recovery during the first seven days post transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RFG</measure>
    <time_frame>1 month</time_frame>
    <description>Absence of a recovery renal function at 1 month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDRD</measure>
    <time_frame>1 year</time_frame>
    <description>Modification of Diet in Renal the Disease at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSR</measure>
    <time_frame>1 year</time_frame>
    <description>graft survival rate at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Biopsie results</measure>
    <time_frame>3 months</time_frame>
    <description>Results of analyzes of kidney biopsies punctures to 3 months.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Transplantation</condition>
  <condition>Kidney</condition>
  <arm_group>
    <arm_group_label>Kidney : perfusion device lifeport</arm_group_label>
    <description>Each donor (n=140) will provide one kidney for pulsatile perfusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kidney : perfusion device waves</arm_group_label>
    <description>Each donor (n=140) will provide one kidney for continuous perfusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LifePort® perfusion device</intervention_name>
    <description>Renal Perfusion with LifePort® perfusion device</description>
    <arm_group_label>Kidney : perfusion device lifeport</arm_group_label>
    <other_name>A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Waves perfusion device</intervention_name>
    <description>Renal Perfusion with Waves perfusion device</description>
    <arm_group_label>Kidney : perfusion device waves</arm_group_label>
    <other_name>B</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        RENAL Donors and recipients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        RENAL Donors:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Deceased donor in brain-dead&#xD;
&#xD;
          -  Donor presenting the expanded criteria of kidney removal (ECD criteria: elderly over&#xD;
             60 or aged 50 to 59 years and has two of the three following criteria: hypertension,&#xD;
             stroke deaths, serum creatinine&gt; 1.5 mg / dL)&#xD;
&#xD;
          -  Possibility of both kidneys perfused machines&#xD;
&#xD;
          -  Sampling of both kidneys, for two distinct recipients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
&#xD;
        RENAL recipients:&#xD;
&#xD;
        The grafts are addressed to transplant centers in France according to the distribution&#xD;
        rules of the National Center of Distribution of transplants . (Pôle National de Répartition&#xD;
        des Greffons (PNRG).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe VENHARD, MD-PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coordination Hospitalière de PMO , Pôle USSAR-Anestéthésie -Réa CHU-ANGERS</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordination Hospitalière de PMO-Anestésiste -réanimateur, CHU-Bordeaux -GROUPE HOSPITALIER PELLEGRIN DAR I</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD-Vendée-Les Oudairies</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordination des prélèvements d'organes et de Tissus- CHU-Limoges -CHU- DUPUYTREN</name>
      <address>
        <city>Limoges</city>
        <zip>84042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chirurgien-Chirurgie de la transplantation et d'Urologie, Pavillon V, Hôpital Edouard HERRIOT</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordination des prélèvements d'organes et de Tissus,CHU-NANTES</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordination des prélèvements d'organes et de Tissus Pôle Anesthésie-Réanimations,University Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 5, 2016</study_first_submitted>
  <study_first_submitted_qc>July 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal infusion</keyword>
  <keyword>Renal infusion device</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

